Zepbound vs. Mounjaro: Same Drug, Different Label, Price, Coverage
Price verification — October 26, 2026
This article includes an older pricing snapshot. Older amounts, coupons and annual totals below are historical illustrations, not current checkout quotes.
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Clinical program fees: Ivím lists a $74.99/month membership with medication billed separately. Sesame lists care from $59/month on a 12-month commitment; month-to-month costs more, and medication is separate. These are care fees, not all-inclusive drug prices. Official source
- Sesame annual-commitment terms: Official source.
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due.
Zepbound and Mounjaro are the same medicine: tirzepatide, made by Eli Lilly, in the same 2.5 mg to 15 mg once-weekly doses. What differs is the FDA label, and the label decides who pays. As of October 2026, Mounjaro is the on-label choice for type 2 diabetes, while Zepbound is the on-label choice for weight management and sleep apnea, and Zepbound is usually the cheaper cash option at $299 to $449 a month (with on-time refills) versus $499 for Mounjaro.
Key takeaways
- Same molecule, same dose strengths, same weekly schedule. You would never take both; Zepbound's label says combining it with other tirzepatide products is not recommended.
- Mounjaro is approved for blood sugar control in type 2 diabetes (ages 10 and up) and, since August 28, 2026, to lower the risk of heart attack, stroke and cardiovascular death in high-risk adults with type 2 diabetes.
- Zepbound is approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity.
- Paying cash through LillyDirect, Zepbound runs $299 to $449 a month (with a 45-day refill rule on higher doses); Mounjaro starts at $499 a month at every dose.
- On Medicare, Mounjaro goes through your regular Part D plan for diabetes, while the Zepbound KwikPen is covered for weight loss through the temporary Medicare GLP-1 Bridge at a $50 copay.
What is actually the same
Both brands contain tirzepatide, a once-weekly injection that acts on both GIP and GLP-1 receptors. Both labels start at 2.5 mg for four weeks and step up in 2.5 mg increments, with 15 mg as the top dose (Zepbound prescribing information; Mounjaro prescribing information).
The devices now match too. Both labels list a single-dose pen, a single-dose vial and a four-dose KwikPen that holds a month of treatment. The FDA cleared KwikPen versions of both brands in late January 2026 (Fierce Pharma).
Because the drug is identical, the Zepbound label lists "coadministration with other tirzepatide-containing products" as not recommended (Zepbound prescribing information). If you are moving from one brand to the other, your prescriber handles how the dose carries over.
Zepbound vs. Mounjaro at a glance
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved uses | Blood sugar control in type 2 diabetes; lowering cardiovascular event risk in high-risk adults with type 2 diabetes | Chronic weight management; moderate to severe obstructive sleep apnea in adults with obesity |
| Approved ages | Adults and children 10+ (pediatric max 10 mg) | Adults |
| Dose range | 2.5 mg to 15 mg weekly | 2.5 mg to 15 mg weekly (maintenance 5, 10 or 15 mg; OSA 10 or 15 mg) |
| Forms | Single-dose pen, vial, KwikPen | Single-dose pen, vial, KwikPen |
| List price | About $1,112 per 28 days | Varies by form |
| LillyDirect self-pay | Starting at $499/month, all doses | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with on-time refill) |
| Medicare route | Regular Part D plan for diabetes | KwikPen via Medicare GLP-1 Bridge, $50/month, through 2027 |
Sources: Lilly prescribing information for Mounjaro and Zepbound (both revised 8/2026); Mounjaro FAQ; LillyDirect pages for Mounjaro and Zepbound; NPR via WLRN. Prices as of October 2026.
The labels are the real difference
Mounjaro: diabetes and, now, heart protection
Mounjaro is approved "to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus" (Mounjaro prescribing information). Lilly's own patient FAQ is blunt about the rest: "Mounjaro is not a weight loss drug" (Mounjaro FAQ).
On August 28, 2026, the FDA added a second use: lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk. It rests on SURPASS-CVOT, which randomized 13,299 adults with diabetes and heart disease to tirzepatide or Trulicity 1.5 mg. Over a median of about four years, tirzepatide was non-inferior, with an 8% lower event rate (hazard ratio 0.92; 95.3% CI 0.83 to 1.01), though superiority over Trulicity was not established (Eli Lilly). That heart indication sits on the Mounjaro label only.
Zepbound: weight and sleep apnea
Zepbound is approved, alongside diet and activity, to reduce and maintain weight in adults with obesity, or with overweight plus at least one weight-related condition. In December 2024 it became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity (FDA).
The overlap is real. An adult with type 2 diabetes and overweight can fit Zepbound's weight-management criteria too, so for some people the choice of brand is a prescribing and coverage decision rather than a medical one.
Results: same drug, different trial populations
Zepbound's headline trial, SURMOUNT-1, enrolled adults with obesity but without diabetes. At 72 weeks, average weight change was −15% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg, versus −3.1% on placebo (American College of Cardiology summary).
Mounjaro's trials enrolled people with type 2 diabetes and measured A1C first. In SURPASS-2, tirzepatide lowered A1C by 2.01 to 2.30 points over 40 weeks, and weight fell 7.6 to 11.2 kg depending on dose (Eli Lilly SURPASS-2 results). Lilly's FAQ summarizes the diabetes studies as roughly 12 to 25 pounds of weight loss from the 5 mg to 15 mg doses (Mounjaro FAQ).
These numbers come from different people over different time frames. They do not mean one brand works better. The molecule is the same; the trials asked different questions.
Comparing tirzepatide options?
See how current GLP-1 programs price Zepbound and other options before you talk to a prescriber.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Price: where the two brands split
Mounjaro's list price is about $1,112 for a 28-day supply (Mounjaro FAQ). Few people pay that, but it sets the baseline for insurers and for anyone paying retail.
Lilly sells both brands directly to cash-paying patients through LillyDirect. The pricing structures are different, and the cheaper one depends on your dose and refill habits.
| Dose | Zepbound self-pay (vial or KwikPen) | Mounjaro self-pay |
|---|---|---|
| 2.5 mg | $299 | From $499 |
| 5 mg | $399 | From $499 |
| 7.5 mg | $449 with refill within 45 days; otherwise $499 | From $499 |
| 10, 12.5, 15 mg | $449 with refill within 45 days; otherwise $699 | From $499 |
Source: LillyDirect Zepbound (page updated September 2026) and Mounjaro (updated October 2026). Monthly supply is 28 days. Needles and syringes are extra.
Two details matter. First, Zepbound's $449 price at 7.5 mg and above requires refilling within 45 days through Lilly's Zepbound Journey Program; miss that window at 10 mg or higher and the price jumps to $699, which is more than Mounjaro's $499 (LillyDirect). Second, these prices date to a December 2025 vial price cut that Lilly announced weeks after its pricing agreement with the federal government; before that, most Zepbound vial doses were $499 (Fierce Pharma). Lilly says prices can change without notice.
Coverage: who pays for which brand
Commercial insurance
Mounjaro's savings card can bring the copay to as little as $25 for up to a three-month prescription if your plan covers it. If your plan does not cover Mounjaro, the card can bring the price to as low as $499 a month. Either way, the card requires an FDA-approved use, which for Mounjaro means type 2 diabetes, and excludes Medicare and Medicaid enrollees (GoodRx).
Zepbound's card offers a similar $25 floor when your plan covers it. Coverage for weight-loss drugs is patchier. Data from MMIT cited by GoodRx (as of August 2025) showed Zepbound pens covered for about 71% of commercial enrollees but vials for only about 40%, with prior authorization common for both (GoodRx).
Medicare
If you take Mounjaro for type 2 diabetes, it runs through your regular Part D plan at that plan's price. For weight loss, Medicare launched the GLP-1 Bridge on July 1, 2026, running through December 31, 2027. It covers the Zepbound KwikPen (plus Wegovy and the Foundayo pill) for a flat $50 a month. Eligibility requires Part D enrollment and a BMI of 35 or higher, or 27 or higher with a qualifying condition, plus prior authorization (NPR via WLRN). The $50 copay does not count toward the Part D out-of-pocket cap.
Which one fits your situation
- You have type 2 diabetes and insurance. Mounjaro is the on-label brand, it carries the new cardiovascular indication, and diabetes coverage is usually the more established path.
- You do not have diabetes and want weight loss or sleep apnea treatment. Zepbound is the on-label brand. Mounjaro would be off-label, and its savings card would not apply.
- You are paying cash with no diabetes. Zepbound through LillyDirect is cheaper at every dose, as long as you refill on time at 7.5 mg and up.
- You are on Medicare without diabetes. The Zepbound KwikPen through the GLP-1 Bridge, at $50 a month, is the route Medicare has opened.
- You are under 18 with type 2 diabetes. Only Mounjaro is labeled for ages 10 and up.
The verdict
Do not choose between Zepbound and Mounjaro on effectiveness; they are the same drug. Choose on the label that matches your diagnosis, because that decides your coverage and price. With type 2 diabetes, Mounjaro is the default, and since August 2026 it is the brand with a heart-risk indication. Without diabetes, Zepbound is the on-label, cheaper option, at $299 to $449 a month cash or $50 a month through Medicare's Bridge. Bring your diagnosis, plan details and dose to your prescriber and let the label do the sorting.
Check current tirzepatide pricing
Prices and programs changed several times in 2026, so compare what providers charge today.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is Zepbound the same drug as Mounjaro?
Yes. Both contain tirzepatide made by Eli Lilly, in the same 2.5 mg to 15 mg once-weekly doses. They differ in FDA-approved uses, pricing programs and how insurers and Medicare cover them.
Can Mounjaro be prescribed for weight loss?
Mounjaro is approved for type 2 diabetes and for lowering cardiovascular risk in high-risk adults with type 2 diabetes, not for weight loss. Lilly's FAQ states that Mounjaro is not a weight loss drug, and its savings card requires an FDA-approved use.
Which is cheaper without insurance, Zepbound or Mounjaro?
As of October 2026, LillyDirect lists Zepbound at $299 to $449 a month depending on dose, with the $449 price at higher doses requiring a refill within 45 days. Mounjaro self-pay starts at $499 a month for every dose.
Does Medicare cover Zepbound?
Through the Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027, the Zepbound KwikPen is covered for weight loss at a $50 monthly copay for eligible Part D enrollees with prior authorization. Mounjaro for type 2 diabetes goes through the regular Part D plan.
Can you take Zepbound and Mounjaro together?
No. Zepbound's prescribing information says coadministration with other tirzepatide-containing products is not recommended, since both brands are the same drug.
Sources
- Mounjaro (tirzepatide) Prescribing Information, Eli Lilly, revised 8/2026
- Zepbound (tirzepatide) Prescribing Information, Eli Lilly, revised 8/2026
- FDA approves Lilly's Mounjaro to reduce cardiovascular risk, Eli Lilly, August 28, 2026
- FDA Approves First Medication for Obstructive Sleep Apnea, FDA, December 20, 2024
- Mounjaro Frequently Asked Questions, Eli Lilly
- Zepbound self-pay pricing, LillyDirect
- Mounjaro self-pay pricing, LillyDirect
- Lilly adds multidose Zepbound pens to self-pay menu after FDA nod, Fierce Pharma, February 2026
- Lilly joins Novo in GLP-1 self-pay price cuts, Fierce Pharma, December 2025
- SURMOUNT-1 trial summary, American College of Cardiology
- SURPASS-2 results, Eli Lilly
- Mounjaro ways to save, GoodRx, August 2026
- Zepbound cost and coverage, GoodRx, May 2026
- A new Medicare option for weight-loss drugs is coming, NPR via WLRN, May 6, 2026
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.